Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessClene Inc. (CLNN:NASDAQ) Earnings Preview: A Critical Moment Ahead

Clene Inc. (CLNN:NASDAQ) Earnings Preview: A Critical Moment Ahead

Add to Favorite
Added to Favorite


On Friday, May 10, 2024, Clene Inc. (CLNN:NASDAQ), a late clinical-stage biopharmaceutical company, is set to unveil its quarterly earnings before the market opens. Analysts on Wall Street are predicting an earnings per share (EPS) of -$0.09 for the quarter, with expected revenue figures reaching $120,000. This anticipation sets a critical stage for CLNN, especially considering its recent financial performance and operational highlights.

In its latest financial disclosure, CLNN reported a quarterly loss of $0.09 per share, exactly in line with the Zacks Consensus Estimate, showcasing an improvement from the previous year’s loss of $0.15 per share. However, the company faced a revenue shortfall, posting only $0.07 million for the quarter ended March 2024, which fell short of the Zacks Consensus Estimate by a significant 54.38%. This revenue figure also marked a decrease from the previous year’s revenue of $0.11 million. Despite these challenges, it’s noteworthy that Clene has surpassed consensus EPS estimates in three out of the past four quarters, indicating a potential for resilience and recovery in its financial performance.

Clene’s focus on developing treatments for neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), remains a cornerstone of its operational strategy. The company highlighted progress in its CNM-Au8 clinical program for MS, sharing key findings from the long-term extension of the Phase 2 VISIONARY-MS clinical trial. These findings demonstrated significant evidence of repair and remyelination, with statistically significant changes from the original baseline. Such advancements not only underscore Clene’s commitment to its research and development efforts but also bolster its potential to make meaningful contributions to the treatment of neurodegenerative diseases.

Financially, Clene has bolstered its position through a substantial sub-award of $7.3 million from a National Institutes of Health (NIH) grant for an ALS Expanded Access Program. As of March 31, 2024, the company reported having cash, cash equivalents, and marketable securities totaling $27.9 million. This financial cushion could play a pivotal role in sustaining its research and development activities, especially in light of its recent revenue shortfalls.

The stock performance of CLNN has also seen fluctuations, with its price moving to $0.396, marking an increase of approximately 1.56%. Despite the volatility, with prices ranging from a low of $0.25 to a high of $1.09 over the past year, Clene’s market capitalization of roughly $50.86 million, alongside a trading volume of 132,718 shares, reflects a level of investor interest and market engagement. As Clene Inc. prepares to release its quarterly earnings, stakeholders and investors will be keenly watching for signs of financial stability and progress in its clinical programs, which could influence the company’s trajectory in the competitive biopharmaceutical landscape.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Exelixis Initiated at Buy with Promising Growth Outlook

Brookline Capital Markets analysts initiated coverage of Exelixis (NASDAQ:EXEL)...

SoundHound AI Price Target Boosted to $26 Amid Surging Demand and Strategic Growth

H.C. Wainwright analysts significantly raised the price target for...

Datadog’s Growth Potential Sparks Price Target Boost to $200

Loop Capital analysts raised their price target for Datadog...

Mizuho Raises UGI Corporation Price Target Amid Confidence in Strategic Shift

Mizuho analysts raised their price target for UGI Corporation...